Today, 3-Methoxy-4-ethoxyphenethylamine is a topic of great relevance in the world. For years, 3-Methoxy-4-ethoxyphenethylamine has been the subject of debate and analysis in various areas, generating conflicting opinions and awakening interest in a wide spectrum of society. In this article, we will delve into the world of 3-Methoxy-4-ethoxyphenethylamine to delve into its importance, its implications and its evolution over time. Through a detailed exploration of 3-Methoxy-4-ethoxyphenethylamine, we will seek to shed light on this highly relevant topic and offer an enriching perspective that allows the reader to further understand its impact on today's world.
This article relies largely or entirely on a single source. (November 2022) |
![]() | |
Names | |
---|---|
Preferred IUPAC name
2-(4-Ethoxy-3-methoxyphenyl)ethan-1-amine | |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
ECHA InfoCard | 100.199.597 |
EC Number |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C11H17NO2 | |
Molar mass | 195.262 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
|
MEPEA, or 3-methoxy-4-ethoxyphenethylamine, is a lesser-known psychedelic drug. MEPEA was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 300 mg, and the duration unknown.[1] MEPEA produces a light lifting feeling and a +1 on the Shulgin Rating Scale. Very little data exists about the pharmacological properties, metabolism, and toxicity of MEPEA.